<DOC>
	<DOC>NCT01375764</DOC>
	<brief_summary>The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia unable to tolerate an effective dose of a statin.</brief_summary>
	<brief_title>Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hyperlipidemias</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Male or female ≥ 18 to ≤ 75 years of age On a statin or a low dose statin with stable dose for at least 4 weeks Lipid lowering therapy has been stable prior to enrollment Fasting triglycerides must be &lt; 400 mg/dL. Subject not at LDLC goal New York Heart Association (NYHA) III or IV heart failure or known left ventricular ejection fraction &lt; 30% Uncontrolled cardiac arrhythmia Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization Type 1 diabetes or newly diagnosed type 2 diabetes (HbA1c &gt; 8.5%) Uncontrolled hypertension</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Proprotein convertase subtilisin/kexin type 9 (PCSK9)</keyword>
	<keyword>Cholesterol</keyword>
	<keyword>High Cholesterol</keyword>
	<keyword>Raised Cholesterol</keyword>
	<keyword>Elevated Cholesterol</keyword>
	<keyword>Statin intolerant</keyword>
	<keyword>Hypercholesterolemia</keyword>
</DOC>